In line with this concept, we showed that ICs are sequentially acquired by tumor–specific CD8 T cells at the tumor site, leading to a terminally exhausted population characterized by TIM-3 expression, the latter being acquired at late stages after PD-1, TIGIT, and CTLA-4 expression acquisition (7). The gene discussed is HAVCR2; the disease is neoplasm.